Beijing Aosaikang Pharmaceutical: 2024 Interim Performance Forecast

Sensex a shareJul 12 12:00 ET · Announcements

Beijing Aosaikang Pharmaceutical (002755.SZ): Expects a profit of 66 million to 85 million yuan in the first half of the year, achieving a turnaround from losses in the same period last year.

On July 12th, Gelunhui announced that Beijing Aosaikang Pharmaceutical (002755.SZ) released its performance forecast for the first half of 2024. According to preliminary estimates by the financial department, it is expected to achieve a net income of 66 million yuan to 85 million yuan attributable to the shareholders of the listed company in the first half of 2024, compared with a loss of 158.4523 million yuan in the same period last year. The net income after deducting non-recurring gains and losses is 45 million yuan to 58 million yuan, compared with a loss of 183.5443 million yuan in the same period last year. The basic earnings per share are 0.07 yuan/share to 0.09 yuan/share. Reasons for the performance changes: 1. Increase in revenue: the company's anti-infection products...

Gelonghui FinanceJul 12 06:05 ET

As of June 20, 2024, the number of shareholders in Beijing Aosaikang Pharmaceutical (002755.SZ) was 19,640.

Beijing Aosaikang Pharmaceutical (002755.SZ) stated on the investor interaction platform on July 5th that as of June 20, 2024, the number of shareholders in the company is 19,640.

Gelonghui FinanceJul 5 06:06 ET

Beijing Aosaikang Pharmaceutical (002755.SZ): Subsidiary injection of foscarnet disodium and pyrimethamine obtained pharmaceutical registration certificate.

On July 1st, Gelunhui announced that its wholly-owned subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd. ('the Company'), has recently received from the National Medical Products Administration (NMPA) the registration certificate for the injection of fosaprepitant dimeglumine. Fosaprepitant dimeglumine is a prodrug of aprepitant, and its antiemetic effect comes from aprepitant. Fosaprepitant dimeglumine can be transformed into aprepitant within 30 minutes after intravenous administration. Aprepitant selectively blocks neurokinin-1 (NK-1) receptors, thereby inhibiting chemotherapy-induced vomiting. It is mainly used for prophylaxis.

Gelonghui FinanceJul 1 04:19 ET

Osecon (002755.SZ): net loss of 149 million yuan in 2023

On April 28, Ge Longhui (002755.SZ) released its 2023 annual report. During the reporting period, the company's operating income was 1,443 million yuan, a year-on-year decrease of 22.92%; net loss attributable to shareholders of listed companies was 149 million yuan; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 227 million yuan; basic loss per share was 0.16 yuan/share.

Gelonghui FinanceApr 28 06:39 ET

Osecon (002755.SZ) announced first-quarter results, net profit of 31.5547 million yuan, turning a loss into a profit

According to Zhitong Finance App News, Osecon (002755.SZ) released its report for the first quarter of 2024. The company's operating income was 448 million yuan, up 32.47% year on year; net profit attributable to shareholders of listed companies was 31,5447 million yuan, which turned a loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 235.361 million yuan; basic income per share was 0.03 yuan/share.

Zhitong FinanceApr 28 04:23 ET